Despite the survival benefits gained from trastuzumab therapy, many patients with metastatic HER2-positive breast cancer do not respond to initial trastuzumab treatment (de novo resistance) and the majority of trastuzumab-responsive patients develop resistance within 1 year of treatment initiation [8, 9]. Here, ERBB2 is linked to breast cancer.